Acute heart failure with preserved ejection fraction demands targeted medical intervention, a state-of-the-art review published by an international expert group in the Cardiac Failure Review reveals. The condition presents unique diagnostic and management challenges for healthcare professionals. It is characterized by a dysfunctional ventricle alongside patient comorbidities and acute triggers.
Targeted Interventions Required for Complex Heart Failure
Hemodynamic Pressures Drive Systemic Congestion
Patients experiencing the condition typically display pulmonary or systemic congestion. This distress is driven by abrupt increases in left-sided filling pressures.
According to the expert group review published in Cardiac Failure Review, these elevated pressures stem from cardiac and arterial stiffness. Neurohormonal activation and systemic inflammation accelerate this stiffness. Consequently, clinical presentations are frequently heterogeneous. They reflect a complex interplay between baseline comorbidities, the severity of acute triggers, and underlying hemodynamic abnormalities.
Diagnostic Demographics and Clinical Markers
Affected individuals are typically older and more frequently female. They present a high burden of cardiometabolic, renal, arrhythmic, ischemic, and inflammatory conditions that heighten vulnerability to rapid decompensation.
Diagnosis relies on an integrated evaluation. Clinicians utilize the clinical context, echocardiographic findings, and adjusted thresholds of natriuretic peptides. Invasive or stress hemodynamics supplement these measures when initial test results remain uncertain.
Personalized Decongestion and Disease-Modifying Therapies
Effective management demands individualized decongestion protocols paired with the direct treatment of acute precipitants.
According to the expert panel recommendations, early initiation of disease-modifying therapies following stabilization significantly improves clinical outcomes. These interventions include sodium–glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists.
Structured Follow-Up to Prevent Readmissions
The condition follows a relapsing-remitting trajectory.
To combat this, clinicians emphasize structured follow-up, ongoing comorbidity management, and proactive preventive strategies to reduce hospital readmissions.
Keep reading